Trials Sponsors Conditions Drugs Pricing

Conditions

Therapeutic Plasma Exchange

Keywords

Therapeutic plasma exchangeanti-SARS-CoV-2 antibodies

Outcome Measures

Primary Outcomes (1)

Analysis of the variation of the anti-SARS-CoV-2 antibodies with plasma exchange procedures
Evolution of anti-SARS-CoV-2 antibodies titre over time in vaccinated adult patients treated with TPE.
3 months

Study Arms (1)

Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.

OTHER

Assessment of the possible variation of anti-SARS-CoV-2 antibody titer in adult patients regularly treated with therapeutic plasma exchange. For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session.

Diagnostic Test: Evolution of antibodies titre

Interventions

Evolution of antibodies titreDiagnostic test

For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session.

Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Adult patients vaccinated against SARS-CoV-2 (any type of vaccine) and regularly receiving therapeutic plasma exchange in the adult hematology department of the Cliniques universitaires Saint Luc.

You may not qualify if:

Sponsors & Collaborators

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Otherlead

Study Sites (1)

Cliniques universitaires Saint-Luc

Brussels, International, 1200, Belgium

Study Officials

Catherine Lambert, Pr
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
PRINCIPAL INVESTIGATOR

Enrollment

15 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 30, 2021

First Posted

January 13, 2022

Study Start

September 8, 2021

Actual (reported)

IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON ACQUIRED VACCINAL ANTI-SARS-CoV-2 ANTIBODIES.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations